Cyprotex's P2P Acquisition

Cyprotex raised a round of funding on December 15, 2016. Investors include Evotec.

Cyprotex is a drug discovery company and specialist pre-clinical contract research organization in ADME-Tox and DMPK. The Group uses experimental screening, virtual screening, and discovery partnershi…

Articles about Cyprotex's P2P Acquisition: